Endocrine oncology

Tumor-Infiltrating Lymphocytes Assessed Using the International Tumor-infiltrating Lymphocytes (TILs) Working Group System Are Not Prognostic in Medullary Thyroid Cancer

ThyroidPublished Retrospective cohort study

Authors' conclusion

In our study, the prognostic value of TILs in MTC was limited. Even high-grade MTC can be considered an immune quiescent tumor, and the adverse prognostic factors associated with higher grade tumors outweigh the marginal increase in immune recognition associated with a slight increase in TILs.

Study context

Population
Patients with primary medullary thyroid cancer (MTC) treated surgically 1995–2016, Royal North Shore Hospital, Sydney, Australia
Participants
71 patients
Exposure
Very low vs low TILs
Outcome
Increasing TILs and outcomes (Cox regression)
Follow-up
Median (IQR) 69 (90) months
Methodological detailssingle-centre
  • Single-centre

Main finding

As reported in the abstract

median (IQR) follow-up 69 (90) months
Low vs Very lowOdds ratio (CI)P value
Local recurrence; log-rank p = 0.022
1.94(0.61–6.16)
P = 0.26
Reduced disease-specific survival; log-rank p = 0.015
5.11(1.01–26.0)
P = 0.049
All patients with MTC had low TILs, median (range)
3% (0-10%)

Observational data: associations, not effects.

Further findings

Association of high International Medullary Thyroid Cancer Grading System (IMTCGS) grade with increased TILs

High IMTCGS grade, OR (CI); only prognostic factor significantly associated with increased TILs
7.29 (1.21-43.90), p = 0.015

Multivariable logistic regression

No significant association between TILs and local recurrence or disease-specific survival

Original publication

Tumor-Infiltrating Lymphocytes Assessed Using the International TILs Working Group System Are Not Prognostic in Medullary Thyroid Cancer. Thyroid. Published 27 January 2025. doi:10.1089/thy.2024.0595

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.